Gene · 5889
RAD51C: RAD51 paralog C
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RAD51C: RAD51 paralog C. Genes, record 5889. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5889
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O43502 | DNA repair protein RAD51 homolog 3 | 376 | 17 | Ensembl, GeneID, HGNC |
Source UniProt
Patents26
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4641201 A2 | 2025-10-29 | 5973 | O43502 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 5973 | O43502 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 8031 | O43502 | Espacenet |
| US 11597924 B2 | 2023-03-07 | 71 | O43502 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 71101 | O43502 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 174072 | O43502 | Espacenet |
| US 10501513 B2 | 2019-12-10 | 8031 | O43502 | Espacenet |
| US 10207988 B2 | 2019-02-19 | 164 | O43502 | Espacenet |
| JP 2017197545 A | 2017-11-02 | 32732 | O43502 | Espacenet |
| US 9587003 B2 | 2017-03-07 | 8031 | O43502 | Espacenet |
1 to 10 of 26
See all 26 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,650
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RAD51C papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 85 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 50 | 2025 |
| P50CA116201 | Mayo Clinic Breast Cancer SPORE | 27 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 23 | 2025 |
| P50CA136393 | Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancer | 20 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 17 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 17 | 2025 |
| P30CA033572 | Cancer Center Support Grant | 14 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 12 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 12 | 2025 |
1 to 10 of 1,650Source NIH's project files
See all 1,650 nih grantsPapers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Prevalence of pathogenic germline variants and indications for testing in a diverse community-based endometrial cancer cohort. | Gynecol Oncol | 2026 | 42822083 | PubTator, text mining | PubMed |
| Genome-Wide CRISPR Screens Identify Genome Stability as Regulator of the Cellular Sensitivity to Environmentally Relevant Bisphenol A Exposure. | Biomolecules | 2026 | 42793135 | PubTator, text mining | PubMed |
| Breast-Ovarian Hereditary Cancer Syndrome: Beyond BRCA1 and BRCA2. | Curr Oncol | 2026 | 42782902 | PubTator, text mining | PubMed |
| SCRMP-mediated SUMOylation of CSNK2B facilitates DNA damage repair to promote cisplatin resistance in small cell lung cancer. | Sci Transl Med | 2026 | 42777084 | PubTator, text mining | PubMed |
| Potential of RAD51C as a hub gene and therapeutic target in bladder cancer: insights from bioinformatics and experimental analysis. | Int J Surg | 2026 | 42682403 | PubTator, text mining | PubMed |
| Distinct functions of mammalian RAD51 paralogs in genome maintenance. | Biochem Soc Trans | 2026 | 42682019 | PubTator, text mining | PubMed |
| Risk-reducing gynecologic surgery in non-BRCA cancer predisposition mutations: a multi-institutional study. | Int J Gynecol Cancer | 2026 | 42648957 | PubTator, text mining | PubMed |
| RAD51C breast cancer-identified variants with attenuated homologous recombination function exhibit sensitivity to combined PARP1 and ATR inhibition. | NAR Cancer | 2026 | 42625895 | PubTator, text mining | PubMed |
| From genetic testing to prevention: an integrated clinical pathway for hereditary risk assessment in tubo-ovarian cancer. | Int J Gynecol Cancer | 2026 | 42617415 | PubTator, text mining | PubMed |
| Uncovering Hereditary Risk: Germline Homologous Recombination Repair Variant Spectrum in a Large North Indian Cancer Cohort (INSIGHT-HRR). | JCO Glob Oncol | 2026 | 42594331 | PubTator, text mining | PubMed |
1 to 10 of 3,668
See all 3,668 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5889
GET https://conductscience.org/api/genes/v1/5889/patents?page=2